Immune dysregulation in myelodysplastic syndrome

Hematology Reviews

Volumn 2, Issue 1, 2010, Pages 1-8

  Sugimori, Chiharu ^a   List, Alan F ^a   Epling Burnette, Pearlie K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Autoimmunity; Myelodysplastic syndrome; T lymphocytes; Treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYCLOSPORIN A; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE MARROW DISEASE; CANCER RISK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CHROMOSOME ABERRATION; CLINICAL TRIAL; CYTOPENIA; CYTOTOXIC T LYMPHOCYTE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DRUG BLOOD LEVEL; EPIGENETICS; ERYTHROCYTE TRANSFUSION; GENETIC DISORDER; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOREGULATION; INCIDENCE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; ONSET AGE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; REMISSION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TRISOMY 8; UNSPECIFIED SIDE EFFECT;

EID: 77953456276     PISSN: 19706804     EISSN: 19706790     Source Type: Journal    
DOI: 10.4081/hr.2010.e1     Document Type: Article

References (91)

1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
2. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25:1908-15.
3. Ma X, Does M, Raza A, Mayne ST. yelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109:1536-42.
4. Rollison DE, Howlader N, Smith MT, et al Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
5. Chen B, Zhao WL, Jin J, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005;19:767-75.
6. Lee JH, Shin YR, Lee JS, et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia. 2003;17:305-13.
7. Toyama K, Ohyashiki K, Yoshida Y, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia. 1993;7:499-508.
8. Intragumtornchai T, Prayoonwiwat W, Swasdikul D, et al. Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. Leuk Res 1998;22:453-60.
9. Paydas S, Kocak R. Younger age observation in myelodysplastic syndrome. Leuk Res 1996;20:367.
10. Chatterjee T, Dixit A, Mohapatra M, et al. Clinical, haematological and histomorphological profile of adult myelodysplastic syndrome. Study of 96 cases in a single institute. Eur J Haematol 2004;73:93-7.
11. Mukiibi JM, Paul B. Myelodysplastic syndromes (MDS) in Central Africans. Trop Geogr Med 1994;46:17-9.
12. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
13. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-49.
14. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
15. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-61.
16. Pfeilstocker M, Karlic H, Nosslinger T, et al. Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications. Leuk Lymphoma 2007;48:1900-9.
17. Rigolin GM, Porta MD, Bugli AM, et al. Flow cytometric detection of accelerated telomere shortening in myelodysplastic syndromes: correlations with aetiological and clinical-biological findings. Eur J Haematol 2004;73:351-8.
18. Ohyashiki K, Shay JW, Ohyashiki JH. Lack of mutations of the human telomerase RNA gene (hTERC) in myelodysplastic syndrome. Haematologica 2005;90:691.
19. Hopfer O, Komor M, Koehler IS, et al. DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation. Exp Hematol 2007;35:712-23.
20. Sloand EM, Yong AS, Ramkissoon S, et al. Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci USA 2006;103: 14483-8.
21. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001;98:3058-65.
22. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B J Clin Oncol 2006;24:3895-903.
23. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40.
24. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-7.
25. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57.
26. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65.
27. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86-93.
28. Young NS, Maciejewski J. The pathophysi-ology of acquired aplastic anemia. N Engl J Med 1997;336:1365-72.
29. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997;11:2049-54.
30. Molnar L, Berki T, Hussain A, Nemeth PLosonczy H. The role of TNF-alpha in myelodysplastic syndrome: immunoserologic and immunohistochemical studies. Orv Hetil 2000;141:1807-11.
31. Selleri C, Maciejewski JP, Catalano L, et al. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer 2002;95:1911-22.
32. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998;102: 1314-22.
33. Kochenderfer JN, Kobayashi S, Wieder ED, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppres-sion. Blood 2002;100:3639-45.
34. Epperson DE, Nakamura R, Saunthararajah Y, et al. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001;25:1075-83.
35. Kook H, Zeng W, Guibin C, et al. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp [Hematology Reviews 2010; 2:e1] Hematol 2001;29:1270-7.
36. Baumann I, Scheid C, Koref MS, et al. Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome. Exp Hematol 2002;30:1405-11.
37. Epling-Burnette PK, Painter JS, Rollison DE, et al. Prevalence and clinical association of clonal T-cell expansions in myelodysplastic syndrome. Leukemia 2007;21:659-67.
38. Sloand EM, Rezvani K. The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol. 2008;45:39-48.
39. Sloand EM, Mainwaring L, Fuhrer M, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005;106:841-51.
40. Sloand EM, Kim S, Fuhrer M, et al. Fasmediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002;100:4427-32.
41. Chen G, Zeng W, Miyazato A, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004; 104:4210-8.
42. Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007; 109:2399-405.
43. Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999; 131:401-8.
44. Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuriatype cells in bone marrow failure syndrome. Blood 2002;100:3897-902.
45. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood 2006;107:1308-14.
46. Murakami Y, Kosaka H, Maeda Y, et al. Inefficient response of T lymphocytes to glycol-sylphosphatidylinositol anchor-negative cells: implications for paroxysmal noc-turnal hemoglobinuria. Blood 2002;100: 4116-22.
47. Nagakura S, Ishihara S, Dunn DE, et al. Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro. Blood 2002;100:1031-7.
48. Luzzatto L, Bessler M, Rotoli B. Somaticmutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Cell 1997;88:1-4.
49. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:3699-709.
50. Zou JX, Rollison DE, Boulware D, et al. Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia 2009.
51. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev 2005;204:55-73.
52. Krupica T Jr., Fry TJ, Mackall CL. Autoimmunity during lymphopenia: a two-hit model. Clin Immunol 2006;120:121-8.
53. Kordasti SY, Afzali B, Lim Z, et al. IL-17 producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009;145:64-72.
54. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96:3671-4.
55. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25.
56. Luger S, Sacks N. Bone marrow transplantation for myelodysplastic syndrome--who? when? and which? Bone Marrow Transplant 2002;30:199-206.
57. Marsh J, Schrezenmeier H, Marin P, et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999; 93:2191-5.
58. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colonystimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midollo Osseo (GITMO). Blood 2000; 95: 1931-4.
59. Young N, Griffith P, Brittain E, et al. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood 1988;72:1861-9.
60. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007;21:1387-94.
61. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991;51:669-73.
62. Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003;75:657-62.
63. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B cell and plasma cell apoptosis by multiple pathways. Transplantation 2005;79:1507-15.
64. Haidinger M, Geyeregger R, Poglitsch M, et al. Antithymocyte globulin impairs Tcell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation. Transplantation 2007;84:117-21.
65. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+ Foxp3+ regulatory T cells. J Am Soc Nephrol 2006;17:2844-53.
66. Lan F, Zeng D, Higuchi M, et al. Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versushost disease: natural suppressor cells. J Immunol 2001;167:2087-96.
67. Killick SB, Marsh JC, Gordon-Smith EC, Sorlin L, Gibson FM. Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia. Br J Haematol 2000;108:582-91.
68. Killick SB, Cox CV, Marsh JC, et al. Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti-thymocyte globulin: examination of the role of the Fas-Fas-L interaction. Br J Haematol 2000;111:1164-9.
69. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002;137:156-63.
70. Saunthararajah Y, Nakamura R, Nam JM,et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immu-nosuppression in myelodysplastic syndrome. Blood 2002;100:1570-4.
71. Yazji S, Giles FJ, Tsimberidou AM, et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003;17:2101-6.
72. Steensma DP, Dispenzieri A, Moore SB, et al. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected[Hematology Reviews 2010; 2:e1] anemic patients with myelodysplastic syn-drome. Blood 2003;101:2156-8.
73. Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004;18:460-5.
74. Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk nonsideroblastic myelodysplastic syndromes. Haematologica 2006;91:667-70.
75. Lim ZY, Pearce L, Ho AY, et al. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. BrJ Haematol 2007;138:517-26.
76. Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008;26:2505-11.
77. Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99:699-705.
78. Kapustin SI, Popova TI, Lyschov AA, et al. HLA-DR2 Frequency increase in severe aplastic anemia patients is mainly attributed to the prevalence of DR15 subtype. Pathol Oncol Res 1997;3:106-8.
79. Nakao S, Takamatsu H, Chuhjo T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplasticanemia. Blood 1994;84:4257-61.
80. Maciejewski JP, Follmann D, Nakamura R, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001;98:3513-9.
81. Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003;120:679-84.
82. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-42.
83. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998;100:304-9.
84. Catalano L, Selleri C, Califano C, et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica 2000;85:133-8.
85. Atoyebi W, Bywater L, Rawlings L, et al. Treatment of myelodysplasia with oral cyclosporin. Clin Lab Haematol 2002;24: 211-4.
86. Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res 2003; 27:783-8.
87. Dixit A, Chatterjee T, Mishra P, et al. Cyclosporin A in myelodysplastic syndrome: a preliminary report. Ann Hematol 2005;84:565-8.
88. Chen SC, Jiang B, Da WM, Gong M, Guan M. Curative effects of cyclosporin A therapy upon myelodysplastic syndrome. Zhonghua Yi Xue Za Zhi 2006;86:2711-5.
89. Ishikawa T, Tohyama K, Nakao S, et al. A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-) [Hematology Reviews 2010; 2:e1] CD59(-) blood cells predicts platelet response. Int J Hematol 2007;86:150-7.
90. Cai W, Hu L, Foulkes JG. Transcriptionmodulating drugs: mechanism and selectivity. Curr Opin Biotechnol 1996;7:608-15.
91. Shimamoto T, Iguchi T, Ando K, et al. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Br J Haematol 2001;114:358-61.